Patterns and predictors of statin prescription in patients with type 2 diabetes

Cardiovascular Diabetology

Volumn 8, Issue , 2009, Pages

  Berthold, Heiner K ^a   Gouni Berthold, Ioanna ^b   Böhm, Michael ^c   Krone, Wilhelm ^b   Bestehorn, Kurt P ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d MSD Sharp and Dohme GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ANNEXIN; ASPARTIC PROTEINASE; CALPONIN; COFILIN; CULLIN; CYSTATHIONINE GAMMA LYASE; CYTOCHROME P450; DAXX PROTEIN; DICHLORVOS; ETHANOLAMINE PHOSPHOTRANSFERASE; FENAMIPHOS; GLUCOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN P; INTERMEDIATE FILAMENT PROTEIN; INTERMEDIATE FILAMENT PROTEIN B; ISOCITRATE LYASE; MALATE SYNTHASE; MEFLOQUINE; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; ORGANOPHOSPHATE PESTICIDE; PREALBUMIN; SPHINGOLIPID ACTIVATOR PROTEIN; THIOREDOXIN; TRANSCRIPTION FACTOR DAF 16; UBIQUITIN; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCOSE; VERY LONG CHAIN FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

APOPTOSIS; ARTICLE; CAENORHABDITIS ELEGANS; CELL ADHESION; CELL DEATH; CONTROLLED STUDY; DETOXIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; LARVA; LIPID METABOLISM; MASS SPECTROMETRY; MICROARRAY ANALYSIS; MUSCLE INJURY; MUSCLE TISSUE; NERVE CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PURIFICATION; AGED; ALBUMINURIA; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; DIABETIC ANGIOPATHY; FEMALE; GERMANY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PRACTICE GUIDELINE; RISK FACTOR; STATISTICAL MODEL;

AGED; ALBUMINURIA; ATHEROSCLEROSIS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GERMANY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 66949180859     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-8-25     Document Type: Article

References (40)

1. Haffner SM Lehto S Ronnemaa T Pyorala K Laakso M Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 1998, 339:229-234 10.1056/NEJM199807233390404 9673301
2. Kearney PM Blackwell L Collins R Keech A Simes J Peto R et al Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis Lancet 2008, 371:117-125 10.1016/S0140-6736(08)60761-8 18191683
3. Ryden L Standl E Bartnik M Van den BG Betteridge J de Boer MJ et al Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 2007, 28:88-136 10.1093/eurheartj/ehm124 17220161
4. American Diabetes Association Standards of medical care in diabetes - 2008 Diabetes Care 2008, 31(Suppl 1):S12-S54 10.2337/dc08-S012 18165335
5. Grundy SM Cleeman JI Merz CN Brewer HB Jr Clark LT Hunninghake DB et al Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 2004, 110:227-239 10.1161/01.CIR.0000133317.49796.0E 15249516
6. Berthold HK Gouni-Berthold I Bestehorn KP Bohm M Krone W Physician gender is associated with the quality of type 2 diabetes care J Intern Med 2008, 264:340-350 10.1111/j.1365-2796.2008.01967.x 18397244
7. Berthold H Gouni-Berthold I Bestehorn K Böhm M Krone W Cardiovascular risk factors in patients with type 2 diabetes in Germany Deutsches Ärzteblatt 2007, 104:A861-A867 http://www.aerzteblatt.de/ v4/archiv/pdf.asp?id=58095
8. Wood D Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme Eur Heart J 2001, 22:554-572 10.1053/ euhj.2001.2610 11259143
9. Tonstad S Rosvold EO Furu K Skurtveit S Undertreatment and overtreatment with statins: The Oslo Health Study 2000-2001 J Intern Med 2004, 255:494-502 10.1111/j.1365-2796.2004.01315.x 15049884
10. Abookire SA Karson AS Fiskio J Bates DW Use and monitoring of "statin" lipid-lowering drugs compared with guidelines Arch Intern Med 2001, 161:53-58 10.1001/archinte.161.1.53 11146698
11. Kassenärztliche Vereinigung Nordrhein - nordrheinische Krankenkassenverbände DMP-Vertrag Diabetes mellitus Typ 2 ab 01.07.2008 2008 http://www.kvno.de/importiert/dmp_diab2_vertrag.pdf last accessed November 30, 2008
12. Colhoun HM Betteridge DJ Durrington PN Hitman GA Neil HA Livingstone SJ et al Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial Lancet 2004, 364:685-696 10.1016/S0140-6736(04)16895-5 15325833
13. Shepherd J Barter P Carmena R Deedwania P Fruchart JC Haffner S et al Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study Diabetes Care 2006, 29:1220-1226 10.2337/dc05-2465 16731999
14. Costa J Borges M David C Vaz CA Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: Meta-analysis of randomised controlled trials BMJ 2006, 332:1115-1124 1459619 16585050 10.1136/bmj.38793.468449.AE
15. Bianchi C Miccoli R Penno G Del PS Primary prevention of cardiovascular disease in people with dysglycemia Diabetes Care 2008, 31(Suppl 2):S208-S214 10.2337/dc08-s256 18227487
16. Grundy SM Cleeman JI Merz CN Brewer HB Jr Clark LT Hunninghake DB et al Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Arterioscler Thromb Vasc Biol 2004, 24:e149-e161 10.1161/01.ATV.0000133317.49796.0E 15297292
17. Gouni-Berthold I Berthold HK Mantzoros CS Bohm M Krone W Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes Diabetes Care 2008, 31:1389-1391 10.2337/dc08-0194 18375411
18. Krone W Böhm M [Diabetes mellitus needs unrestricted evaluation of patient data to yield treatment progress. The DUTY Register] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2004, 47:540-546 10.1007/s00103-004-0843-2 15221103
19. Levey AS Bosch JP Lewis JB Greene T Rogers N Roth D A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 1999, 130:461-470 10075613
20. Cederholm J Eeg-Olofsson K Eliasson B Zethelius B Nilsson PM Gudbjornsdottir S Risk prediction of cardiovascular disease in type 2 diabetes: A risk equation from the Swedish National Diabetes Register Diabetes Care 2008, 31:2038-2043 10.2337/dc08-0662 18591403
21. Schwabe U Paffrath D eds Arzneiverordnungs-Report 2003 Springer-Verlag, Berlin, Heidelberg, New York 2003
22. Donnelly LA Doney AS Morris AD Palmer CN Donnan PT Long-term adherence to statin treatment in diabetes Diabet Med 2008, 25:850-855 10.1111/ j.1464-5491.2008.02476.x 18644071
23. Rathmann W Haastert B Icks A Giani G Trends in outpatient prescription drug costs in diabetic patients in Germany, 1994-2004 Diabetes Care 2007, 30:848-853 10.2337/dc06-2000 17392545
24. Collins R Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial Lancet 2002, 360:7-22 10.1016/S0140-6736(02)09327-3 12114036
25. Yang CC Jick SS Testa MA Who receives lipid-lowering drugs: The effects of comorbidities and patient characteristics on treatment initiation Br J Clin Pharmacol 2003, 55:288-298 1884220 12630980 10.1046/ j.1365-2125.2003.01724.x
26. Neutel CI Morrison H Campbell NR de GM Statin use in Canadians: Trends, determinants and persistence Can J Public Health 2007, 98:412-416 17985686
27. Weir MR Microalbuminuria and cardiovascular disease Clin J Am Soc Nephrol 2007, 2:581-590 10.2215/CJN.03190906 17699466
28. Teeling M Bennett K Feely J The influence of guidelines on the use of statins: Analysis of prescribing trends 1998-2002 Br J Clin Pharmacol 2005, 59:227-232 1884758 15676046 10.1111/j.1365-2125.2004.02256.x
29. Ko DT Mamdani M Alter DA Lipid-lowering therapy with statins in high-risk elderly patients: The treatment-risk paradox JAMA 2004, 291:1864-1870 10.1001/jama.291.15.1864 15100205
30. Gnavi R Migliardi A Demaria M Petrelli A Caprioglio A Costa G Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities Eur J Public Health 2007, 17:492-496 10.1093/eurpub/ckm005 17303583
31. Lee HY Cooke CE Robertson TA Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge J Manag Care Pharm 2008, 14:271-280 18439049
32. Shepherd J Blauw GJ Murphy MB Bollen EL Buckley BM Cobbe SM et al Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial Lancet 2002, 360:1623-1630 10.1016/S0140-6736(02)11600-X 12457784
33. Brown MS Goldstein JL Biomedicine. Lowering LDL - not only how low, but how long? Science 2006, 311:1721-1723 10.1126/science.1125884 16556829
34. Agalliu I Salinas CA Hansten PD Ostrander EA Stanford JL Statin use and risk of prostate cancer: Results from a population-based epidemiologic study Am J Epidemiol 2008, 168:250-260 10.1093/aje/kwn141 18556686
35. Wexler DJ Grant RW Meigs JB Nathan DM Cagliero E Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes Diabetes Care 2005, 28:514-520 10.2337/diacare.28.3.514 15735180
36. Ferrara A Mangione CM Kim C Marrero DG Curb D Stevens M et al Sex disparities in control and treatment of modifiable cardiovascular disease risk factors among patients with diabetes: Translating Research Into Action for Diabetes (TRIAD) Study Diabetes Care 2008, 31:69-74 10.2337/dc07-1244 17934157
37. Coleman RL Stevens RJ Retnakaran R Holman RR Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes Diabetes Care 2007, 30:1292-1293 10.2337/ dc06-1358 17290036
38. Mihaylova B Briggs A Armitage J Parish S Gray A Collins R Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: Economic analysis of a randomised trial in 20,536 individuals Lancet 2005, 365:1779-1785 10.1016/S0140-6736(05)63014-0 15910950
39. Brown AF Gross AG Gutierrez PR Jiang L Shapiro MF Mangione CM Income-related differences in the use of evidence-based therapies in older persons with diabetes mellitus in for-profit managed care J Am Geriatr Soc 2003, 51:665-670 10.1034/j.1600-0579.2003.00211.x 12752842
40. Shani M Dresner J Vinker S Achieving target cholesterol levels in diabetic patients: Potency of the statin or potency of the physician? Isr Med Assoc J 2008, 10:354-357 18605358